Health and Life Sciences
Healthcare companies face enormous challenges during this era of reform. The marketplace of the future will require new paradigms to realize the vision of affordability and quality. Change will impact payers, providers, and pharmaceutical companies alike and require unprecedented collaboration at the intersections.
Recognizing the power of a systemic view, healthcare companies are turning to Oliver Wyman. Our deep expertise across the healthcare landscape is centered in integrated health management – a differentiated approach in the marketplace that has been proven to drive critical transformation. Our perspective in life sciences is focused on transformational changes that pharmaceutical and biotechnology companies need to make in a world where product innovation is more challenging and where value is measured in patient outcomes.
Key Capabilities
Integrated Health Management (IHM)
Oliver Wyman’s IHM framework is a comprehensive approach to thinking about care management and delivery, helping healthcare companies shift their business models to compete on the basis of cost and quality of care.
Healthcare Reform
Oliver Wyman advises clients on the key business areas that will be affected by reform and recommends actions to proactively prepare for the post reform marketplace. Oliver Wyman has built the market-leading quantitative model to evaluate the impact of insurance reform on payers. Additionally, our Go-to-Market thought leadership addresses the implications of reform efforts on pharmaceutical and bio-tech sales and marketing practices.
Seniors
Our team of Medicare specialists has helped payers across the U.S. position for success in this high growth but rapidly changing market.
Go-To-Market
Oliver Wyman’s research-driven thought leadership and experience focus on the critical elements of pharmaceutical and biotechnology products - outcomes and value - that will form the future foundation of effective sales and marketing practices.
Licensing
Oliver Wyman has developed licensing strategies to help pharmaceutical and biotech companies assess licensing compound priorities, portfolio risk and return, and competitive advantage. In addition, Oliver Wyman has developed a proprietary platform for valuing and risk-adjusting licensing agreements in transactions.
Global Health
Global health foundations and institutions partner with Oliver Wyman to advance public health through strategies that apply therapeutic technologies and expand access to essential therapies throughout the developing world.
Key Sectors
Pharmaceuticals & Biotechnology
Oliver Wyman partners with leading pharmaceutical and biotechnology companies to address strategic issues pertaining to product innovation, licensing, development, and commercialization.
Health Insurance Payers
Oliver Wyman helps payer organizations across the U.S. to redefine operating strategies that drive near-term operating performance, but also support the advancements necessary for long-term viability and impact.
Healthcare Providers
Oliver Wyman collaborates with provider organizations seeking to establish leadership positions in health management. We provide strategic advice and clinical expertise focused on improving the cost and quality of care by enhancing outcomes and aligning incentives.
